AXGT:NSD-Sio Gene Therapies, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.49

Change

+0.18 (+7.79)%

Market Cap

USD 0.09B

Volume

0.82M

Average Target Price

USD 13.75 (+452.21%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Sciences Ltd. and changed its name to Axovant Gene Therapies Ltd. in March 2019. Axovant Gene Therapies Ltd. was founded in 2014 and is based in London, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+8.61 (+3.95%)

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+5.74 (+1.13%)

USD54.24B 20.76 16.02
MRNA Moderna, Inc

+17.85 (+16.35%)

USD43.20B N/A N/A
SGEN Seagen Inc

+3.67 (+2.22%)

USD29.62B 62.48 65.81
ALXN Alexion Pharmaceuticals, Inc

+0.90 (+0.73%)

USD26.90B 28.53 26.40
RPRX Royalty Pharma plc

+0.63 (+1.54%)

USD25.62B 22.60 9.61
BNTX BioNTech SE

+5.03 (+4.79%)

USD25.27B -99,999.99 N/A
GMAB Genmab A/S

+1.22 (+3.40%)

USD23.59B 26.59 2.65
BGNE BeiGene, Ltd

+21.73 (+8.23%)

USD23.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AXGT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.37% 14% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.37% 14% F 6% F
Trailing 12 Months  
Capital Gain -53.97% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.97% 12% F 5% F
Trailing 5 Years  
Capital Gain -98.20% 9% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.20% 9% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -19.80% N/A N/A 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.80% N/A N/A 10% F
Risk Return Profile  
Volatility (Standard Deviation) 28.57% N/A N/A 51% F
Risk Adjusted Return -69.28% N/A N/A 9% F
Market Capitalization 0.09B 24% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.58 86% B 63% D
Price / Cash Flow Ratio -1.31 18% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -78.49% 35% F 12% F
Return on Assets -37.29% 31% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.65 83% B 82% B-
Short Percent 6.72% 48% F 31% F
Beta 1.58 48% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.